The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
about
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesUse of metformin in diseases of agingRisk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias ToolToward high-throughput phenotyping: unbiased automated feature extraction and selection from knowledge sourcesEstimating causal effects in observational studies using Electronic Health Data: Challenges and (some) solutionsEfficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study.Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes.The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.Gut microbiota and diabetes: from pathogenesis to therapeutic perspective.Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.Pioglitazone: beyond glucose control.IGF-1 and atherothrombosis: relevance to pathophysiology and therapy.The safety of thiazolidinediones.Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies.Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis.Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations.Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes.Omarigliptin for the treatment of type 2 diabetes.Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.Surrogate-assisted feature extraction for high-throughput phenotyping.Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB DatabasRisk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus.Blood pressure, fluid retention and the cardiovascular risk of drugs.The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.Rosiglitazone decreases fasting plasma peptide YY3-36 in type 2 diabetic women: a possible role in weight gain?Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment.Association Between Metformin Adherence and All-Cause Mortality Among New Users of Metformin: A Nested Case-Control Study.The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.
P2860
Q24632655-26D2B45C-8DB6-40F9-8BDE-2F14B4EE6CF5Q26828760-50327F21-1756-4B43-9ED8-1289ED217C32Q28551188-38BFD8AD-A847-44C5-B7A3-3BD8150DA5DCQ28597791-391968C8-1697-446B-A4A6-0C7364DE65C8Q30830592-9A980588-0C63-41E3-A12C-A252D4656A0BQ33447152-1080186C-B0AF-434F-9F91-4E21C03D6E74Q33793434-EE3E11D8-1FCB-4BFC-AE97-55BB632BB41BQ33873053-BEA198B6-1EFF-42DD-B74E-B0F8F86DD906Q35573510-FCEB9B3A-92C4-4F61-A793-B4C9D12C6F9DQ36544845-D7850930-A812-4EE0-9889-AE1C7DB581D9Q36649277-4BF417A3-1A30-49DF-A202-7DD17088B75EQ37776510-6389643A-FED8-4213-A000-3F85F3950E68Q37829755-5FD55E7A-A937-4357-96CA-6E4B441DAA61Q37848841-821FF2FD-C10C-4FEF-8027-920AA20E1804Q38071847-E086661D-DAF8-443A-AD20-D7DD84B07815Q38105641-391C5E6E-3F01-46E2-B51F-A494EA1D877CQ38248399-3006E478-55C5-4425-9518-085CA80CD4C8Q38374279-19A62BA8-41CE-4CE5-A94F-97C173413918Q38641190-6ECE8794-C02B-45BB-B8FC-B841C2B62AA1Q38662690-D448DA22-1E0E-49D6-B3C8-90778F43B0A2Q38825446-5C122027-B041-4C6E-A112-72372F6A8146Q38828606-04008329-B4DE-4727-A606-998FBD52B99AQ38884175-1A11CEE5-50BD-412E-A19E-116923CF724EQ38960765-F669B237-AA13-4D29-AC53-7D89DE439902Q39385499-C2F9B7CA-9FE3-4DAE-9F07-13B4ACE52072Q40795716-7FF95261-C61D-4DC7-AF55-71EFC7E79B9CQ40992057-AB60BDC4-2049-407B-B737-E0E9AE90E62BQ41740997-1F923001-3CB7-438E-A971-34B40F796358Q42485644-F2499AA3-9C64-466D-9F24-363482A1C132Q44964357-C54ED617-F3AB-4A15-B26C-4B07868CF87EQ47261527-632D6D39-67E8-48D3-841C-A2F2F4C7BF9DQ47342804-60878512-EA8C-48AC-B2DF-14A739CF0CADQ48274537-C6141F3B-FCA4-41F3-A297-96E7786ECD43Q49967667-1BF2FCC5-AAF3-4939-B702-120DF3688941Q55078568-FFEF637E-BFFE-41A3-8F8D-74233D3C54F7
P2860
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
The risk of developing coronar ...... eas: a retrospective analysis.
@en
The risk of developing coronar ...... eas: a retrospective analysis.
@nl
type
label
The risk of developing coronar ...... eas: a retrospective analysis.
@en
The risk of developing coronar ...... eas: a retrospective analysis.
@nl
prefLabel
The risk of developing coronar ...... eas: a retrospective analysis.
@en
The risk of developing coronar ...... eas: a retrospective analysis.
@nl
P2093
P1433
P1476
The risk of developing coronar ...... eas: a retrospective analysis.
@en
P2093
Ashish Atreja
Changhong Yu
Kevin M Pantalone
Michael W Kattan
Robert S Zimmerman
Susana Arrigain
P2888
P304
P356
10.1007/S00592-008-0090-3
P50
P577
2009-02-05T00:00:00Z